Christopher Leamon - Nov 1, 2021 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Scientific Officer
Signature
/s/Maria Stahl as Attorney-in-Fact for Christopher Leamon
Stock symbol
FUSN
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
4
Date filed
11/2/2021, 04:37 PM
Next filing
Jan 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +218K $0.00 218K Nov 1, 2021 Common Stock 218K $7.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option shall vest and become exercisable on the first anniversary of the grant date and the remainder shall vest and become exercisable in 36 substantially equal monthly installments thereafter.